The HDAC6 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of human HDAC6 in the A2780 ovarian carcinoma background. This product provides a pooled population of cells with targeted disruption of the HDAC6 gene, enabling robust functional analyses without clonal selection bias. The polyclonal format ensures representation of diverse editing events across the cell pool, making it suitable for high-throughput screening and pathway dissection where population-level phenotypes are informative. Researchers can employ this model to investigate the consequences of HDAC6 ablation in a cancer-relevant context under physiologically relevant polyclonal conditions.
The host A2780 cell line is a well-characterized human epithelial ovarian carcinoma model originally derived from an untreated patient. These cells exhibit adherent growth and retain key oncogenic signaling aberrations typical of high-grade serous ovarian cancer. As a widely employed line in oncology research, A2780 is particularly valued for studies of platinum- and taxane-based drug sensitivity, metastasis, and tumor-stroma interactions. Its genetic background provides a clinically relevant platform for examining the role of epigenetic modifiers such as HDAC6 in tumor progression and therapeutic response.
HDAC6 is a predominantly cytoplasmic histone deacetylase that deacetylates non-histone substrates, including ??-tubulin, Hsp90, and cortactin, thereby modulating microtubule stability, chaperone function, and actin dynamics. Its activity is regulated by upstream signals such as TGF-??1, IL-6, EGF, and Aurora A kinase, and it interfaces with the aggresome-autophagy pathway by interacting with ubiquitin, p97/VCP, and p62/SQSTM1 to facilitate clearance of misfolded protein aggregates. HDAC6-dependent deacetylation of ??-tubulin promotes cell motility, while deacetylation of Hsp90 influences client protein maturation, including key oncogenic regulators. Additionally, HDAC6 participates in NF-??B and TGF-?? signaling cascades, positioning it as a central node in cellular stress responses.
In the A2780 context, loss of HDAC6 function leads to constitutive hyperacetylation of ??-tubulin and Hsp90, impairing aggresome formation and autophagic degradation. This disruption compromises cell migration and invasion, sensitizes cells to proteotoxic stress, and enhances apoptosis induction by chemotherapeutics such as cisplatin and paclitaxel. The polyclonal knockout population thus recapitulates key phenotypes associated with HDAC6 inhibition and offers a powerful system to dissect the role of HDAC6 in ovarian cancer cell survival, chemoresistance, and metastatic dissemination. Moreover, it enables the interrogation of cross-talk between HDAC6-driven protein quality control pathways and oncogenic signaling networks.
This product is ideally suited for a wide range of research applications including ovarian cancer biology, HDAC6 inhibitor validation, autophagy and aggresome studies, microtubule dynamics, and drug resistance mechanisms. Researchers can perform Western blotting and immunofluorescence to monitor acetylation states of ??-tubulin and Hsp90, assess aggresome formation, and evaluate HDAC6 expression levels. Functional assays such as cell migration/invasion, flow cytometry-based apoptosis, and HDAC activity measurements are readily implemented. Additionally, drug sensitivity profiling with standard-of-care agents or experimental HDAC6 inhibitors can be performed using viability or apoptosis readouts. For further experimental details or custom inquiries, please contact Ascent Research.
